Cargando…

Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI

PURPOSE: Oral corticosteroids (OCS) play a role in the treatment of acute chronic obstructive pulmonary disease (COPD) exacerbations; however, chronic use is not recommended due to the high rate of systemic complications, development of comorbidities, and increased mortality. Data assessing the real...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bogart, Michael, Abbott, Carl B, Bangalore, Mohan, McMorrow, Donna, Packnett, Elizabeth R, DiRocco, Kristi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625739/ https://www.ncbi.nlm.nih.gov/pubmed/37933243 http://dx.doi.org/10.2147/COPD.S419272

Ejemplares similares

Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
por: Marín, José M., et al.
Publicado: (2020)

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
por: Kato, Motokazu, et al.
Publicado: (2019)

Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials
por: Hanania, Nicola A, et al.
Publicado: (2021)

Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
por: Mannino, David, et al.
Publicado: (2022)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
por: Bansal, Sandeep, et al.
Publicado: (2021)

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
por: Ismaila, Afisi S., et al.
Publicado: (2022)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma
por: Silver, Jared, et al.
Publicado: (2020)

Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”
por: Marshall, Jonathan, et al.
Publicado: (2023)

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States
por: Silver, Jared, et al.
Publicado: (2023)

Transitions of Care for People with Type 2 Diabetes: Utilization of Antihyperglycemic Agents Pre- and Post-Hospitalization
por: Montejano, Leslie, et al.
Publicado: (2015)

S. A. ff. Dakin
Publicado: (1962)

The ATP Synthase Subunits FfATPh, FfATP5, and FfATPb Regulate the Development, Pathogenicity, and Fungicide Sensitivity of Fusarium fujikuroi
por: Yang, Xin, et al.
Publicado: (2023)

A114 UNIFIED MAGNIFYING ENDOSCOPIC CLASSIFICATION (UMEC) FOR GASTROINTESTINAL LESIONS: A NORTH AMERICAN EDUCATION STUDY
por: Fujiyoshi, M R A, et al.
Publicado: (2023)

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
por: Bogart, Michael, et al.
Publicado: (2023)

Highlights of H→ff at the LHC
por: Chen, Xin
Publicado: (2019)

Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors
por: Journigan, V. Blair, et al.
Publicado: (2014)

Processing, Characterization of Furcraea foetida (FF) Fiber and Investigation of Physical/Mechanical Properties of FF/Epoxy Composite
por: Madival, Abhishek Sadananda, et al.
Publicado: (2022)

Tailoring of corticosteroids in COPD management
por: De Coster, Daan A., et al.
Publicado: (2014)

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
por: Bateman, Eric D, et al.
Publicado: (2014)

Ff-nano, short functionalized nanorods derived from Ff (f1, fd, or M13) filamentous bacteriophage
por: Sattar, Sadia, et al.
Publicado: (2015)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

FfF: Foundations for Food (security) are cellular
por: Nick, Peter, et al.
Publicado: (2023)

One to Two Days of Rest Is Recommended Before Returning to Sport After Intra-Articular Corticosteroid Injection in the High-Level Athlete
por: McMorrow, Katie, et al.
Publicado: (2023)

Effect of 905 MHz microwave radiation on colony growth of the yeast Saccharomyces cerevisiae strains FF18733, FF1481 and D7
por: Vrhovac, Ivana, et al.
Publicado: (2010)

COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
por: Hanania, Nicola A, et al.
Publicado: (2023)

Nebulized corticosteroids in the management of acute exacerbation of COPD
por: Gaude, G. S., et al.
Publicado: (2010)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Inhaled corticosteroids in COPD: Personalising the therapeutic choice
por: Shaw, J A, et al.
Publicado: (2018)

How inhaled corticosteroids target inflammation in COPD
por: Lea, Simon, et al.
Publicado: (2023)

Rational use of inhaled corticosteroids for the treatment of COPD
por: Quint, Jennifer K., et al.
Publicado: (2023)

KEK Flavor Factories workshop (KEK-FF 2023)
Publicado: (2023)

Role of neuropeptide FF in central cardiovascular and neuroendocrine regulation
por: Jhamandas, Jack H., et al.
Publicado: (2013)

The hypothalamic neuropeptide FF network is impaired in hypertensive patients
por: Goncharuk, Valeri D, et al.
Publicado: (2014)

Targeting glioblastoma via intranasal administration of Ff bacteriophages
por: Dor-On, Eyal, et al.
Publicado: (2015)

Evaluating the performance of ReaxFF potentials for sp(2) carbon systems (graphene, carbon nanotubes, fullerenes) and a new ReaxFF potential
por: Fthenakis, Zacharias G., et al.
Publicado: (2022)

Transcription factor FfMYB15 regulates the expression of cellulase gene FfCEL6B during mycelial growth of Flammulina filiformis
por: Liu, Zongqi, et al.
Publicado: (2022)

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
por: Vogelmeier, Claus, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jhe1kt1d3sec201p5rjfq19tbb